Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK wild-type |
| Therapy | Cisplatin + Dalantercept |
| Indication/Tumor Type | head and neck cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK wild-type | head and neck cancer | predicted - sensitive | Cisplatin + Dalantercept | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the addition of Dalantercept (ACE-041) to Platinol (cisplatin) treatment resulted in increased cytoxicity and decreased tumor growth in cell line xenograft models of head and neck cancer (PMID: 26373572). | 26373572 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26373572) | Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors. | Full reference... |